Cybin opened lower at $9.07, compared with its previous close of $9.39. In the last trading session, the stock traded between $8.78 and $9.35. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 1 year ago in Cybin is now worth
$ 114.79
Giving a profit of
$ 14.79 (14.79%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 6 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.52 (-5.51%)
Day High
$9.35
Day Low
$8.78
Day Open
$9.07
Prev Close
$9.39
Volume
9,67,203
1W Return
2.19%
1M Return
-19.50%
3M Return
-12.09%
6M Return
73.98%
1Y Return
14.79%
Fundamentals
Market Cap ($ Mn)
648
PE Ratio
-
PB Ratio
4.39
PEG Ratio
-
ROE
-57.03%
ROCE
-46.24%
EPS (TTM)
$-0.77
Investment Returns
1 Week
2.19%
1 Month
-19.50%
3 Months
-12.09%
6 Months
73.98%
9 Months
36.72%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
27Oct
Helus Pharma appoints Mark Lawson as independent board chair
Mark Lawson appointed independent Chair of the Board, effective immediately. Lawson has over 20 years of private equity and investment banking experience. Co-founders Eric So and Paul Glavine step down from executive roles. So and Glavine remain members of the Board of Directors.
Wells Fargo maintains Overweight rating on Helus Pharma. Price target raised from $16 to $22 by analyst Benjamin Burnett. Target increase represents a 37.5% uplift from previous level.
Helus Pharma Inc. expects topline data from the APPROACH Phase 3 study of HLP003 in Q4 2026. Phase 2 monotherapy study for HLP004 in generalized anxiety disorder is set to initiate in Q1 2027. HLP003 received FDA Breakthrough Therapy Designation, with New Drug Application filing expected in 2028. The HLP004 Phase 2 study will enroll approximately 144 participants to assess 30 mg monotherapy efficacy.
22 days ago
15Oct
Helus Pharma appoints Dr. Suresh Durgam to Board of Directors
Helus Pharma appointed Dr. Suresh Durgam to its Board of Directors. Dr. Durgam previously served as CMO at Intra-Cellular Therapies. Appointment subject to approval by Cboe Canada. Company advances Phase 3 drug HLP003 for major depressive disorder.
